|
| Safe | (i) Minimize off-target toxicity [66] |
| (ii) Without adverse interactions with antivenom |
| (iii) Broad therapeutic index |
|
| Efficacy (in vitro) | (i) Nano- or subsnanomolar in vitro potency (IC50) for scalability [66, 77, 80] |
| (ii) Determination of affinity, minimum active concentrations, physical characteristics, stability, mechanisms of action, dose-response, and drug effects [8, 31, 32, 54, 69, 77, 80–87] |
|
| Efficacy (in vivo) | (i) Tested with both: |
| (a) Minimum acceptable: Pre-mixing of venom and antidote prior to injection (ED50 determination) [32] |
| (b) Ideal: Venom administration prior to administration of antidote [8, 31, 88] |
| (ii) Compatible with standard assessments of coagulation [89] |
|
| Broad Spectrum | (i) Wide target selection (ubiquity and medical importance of inhibitory target amon snake species) [34, 35] |
|
| Heat Stable | (i) Real-time stability studies up to 37°C (±2°C) and relative humidity of 75% (±5%) (WHO “Climatic Zone IVb”) [90] |
|
| Ease of Administration | (i) Oral solution, rectal or nasal formulations |
| (ii) Auto-Injectable [54] |
|
| Bioavailability | (i) For oral formulations, adequate bioavailability in fed state |
|
| Half-life | (i) For field antidotes, half-life of at least 5 to 7 hours [78, 91, 92] |
| (ii) Potential for re-dosing |
|
